Robert Grossberg

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV

Robert Grossberg, Yawei Zhang, Robert Gross · Journal of Clinical Epidemiology · 2004 · 191 citations

Public Health, Clinical Pharmacy, Pharmacotherapy +16

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Cameron R. Wolfe, Kay M Tomashek, Thomas F. Patterson et al. · The Lancet Respiratory Medicine · 2022 · 128 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +3

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Onyema Ogbuagu, Peter Ruane, Daniel Podzamczer et al. · The Lancet HIV · 2021 · 91 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Evolocumab in HIV-Infected Patients With Dyslipidemia

Franck Boccara, Princy Kumar, Bruno Caramelli et al. · Journal of the American College of Cardiology · 2020 · 62 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17